ELVN-002

DRUG3 trials

Sponsors

Enliven Therapeutics Inc., Enliven Therapeutics

Conditions

Colorectal CancerColorectal Cancer and Breast CancerHER2 AmplificationHER2 Gene MutationHER2 Mutant Non-small Cell Lung CancerHER2 Positive Solid TumorsHER2-positive Breast CancerHER2-positive Gastric Cancer

Phase 1

ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

Active, not recruitingNCT05650879

Enliven TherapeuticsHER2 Amplification, HER2 Gene Mutation, HER2 Mutant Non-small Cell Lung Cancer +1

Start: 2023-03-20End: 2026-07-31Target: 198Updated: 2025-07-15

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Active, not recruitingNCT06328738

Enliven TherapeuticsColorectal Cancer, HER2 Amplification, HER2-positive Breast Cancer +2

Start: 2024-05-30End: 2028-07-31Target: 275Updated: 2025-11-19

A Phase 1a/1b Study of ELVN-002 Combined with Trastuzumab in Advanced Stage HER2+ Solid tumors, and ELVN-002 Combined with Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast Cancer

Active, not recruitingCTIS2023-509716-29-00

Enliven Therapeutics Inc.Colorectal Cancer and Breast Cancer, Solid Tumors

Start: 2024-09-23Target: 156Updated: 2025-11-24